Ozempic and semaglutide are back in the headlines—and this week's developments demand attention from anyone considering or currently using GLP-1 medications. In this episode of *Navigating Ozempic*, we break down five critical stories reshaping the conversation around semaglutide, tirzepatide, and Mounjaro.
**What You'll Learn:**
- **Global safety alert**: Namibia's Ministry of Health issues new guidance on ethical prescribing and monitoring for semaglutide and tirzepatide amid surging demand
- **Counterfeit drug danger**: Medical Daily investigates online sellers offering cheap "research-grade" semaglutide—some linked to chemicals used in fentanyl production—and why the FDA considers these products unapproved and potentially dangerous
- **Vision and pancreatitis risks**: NPR's deep dive into nearly 2,000 pancreatitis cases and 1,000 reports of sudden vision loss (NAION) tied to GLP-1 medications since 2024
- **New pediatric guidelines**: The WHO's first-ever global recommendations for treating childhood obesity, including strict limits on medication use in children and teens
- **Nutrition during weight loss**: Why reduced appetite on Ozempic may lead to protein, vitamin, and hydration deficiencies—and what dietitians recommend
- **Muscle preservation research**: A promising phase 2 study on trevogrumab, designed to protect lean muscle mass during semaglutide-driven weight loss
- **Anti-aging buzz**: Novo Nordisk and Eli Lilly's preliminary research suggesting semaglutide may slow biological aging markers by 2-4 years—and why these early findings need serious scrutiny
- **Future of gener
Podden och tillhörande omslagsbild på den här sidan tillhör
Liquid Studios. Innehållet i podden är skapat av Liquid Studios och inte av,
eller tillsammans med, Poddtoppen.
